Ingredient guide
Compare tirzepatide, Zepbound, Mounjaro, and compounded products, then understand WellForm local and virtual care, pharmacy, and payment steps.
The tirzepatide brand with chronic weight-management indications.
A separate tirzepatide brand approved for type 2 diabetes.
Compounded tirzepatide is not FDA-approved and is not generic Zepbound or Mounjaro.
The decision in plain language
Zepbound and Mounjaro both contain tirzepatide, but a shared ingredient does not erase the different FDA-approved indications, labels, fulfillment, and payment pathways.
A tirzepatide brand with chronic weight-management indications in its prescribing information.
A tirzepatide brand approved to improve glycemic control in adults with type 2 diabetes.
The shared ingredient explains the relationship—not permission to substitute brand names or approved uses.
Compounded tirzepatide is not FDA-approved and is not a generic form of either brand.
The exact product and its approved use must stay explicit throughout evaluation, prescribing, fulfillment, and follow-up.
Your care path
WellForm first identifies what you are asking about, then evaluates clinical fit and explains the exact fulfillment and payment path.
Choose Ankeny or virtual care and tell us the option you want to discuss.
Review goals, history, current treatment, risks, and practical access.
Clarify the exact service or product, care fee, pharmacy path, and what is not included.
Monitor response, barriers, tolerability when relevant, and the next clinical or practical step.
Ready when you are
An ingredient, not a brand · Zepbound and Mounjaro differ · Compounded is a separate category
What happens next
The consultation, payment explanation, and follow-up plan remain visible before you commit.
Select the page-specific interest when you request an Ankeny or virtual visit.
Dr. Patrick Oben reviews clinical fit and explains the differences that matter.
Agree on the care setting, WellForm fee, and any separate pharmacy transaction.
Clinical fit
Medical history and treatment goals are reviewed against the prescribing information for the exact product being considered.
Ongoing care
Response, tolerability, dose decisions, and access are reviewed without assuming that two brands are interchangeable.
Benefits and limits
The exact product and its approved use must stay explicit throughout evaluation, prescribing, fulfillment, and follow-up.
Compare your options
Use the brand pages for product-specific approved-use, fulfillment, and payment details.
Local, virtual, and payment
WellForm medical or support care is one transaction. A prescribed medication is generally a separate transaction with the dispensing pharmacy.
The compounded tirzepatide virtual program starts at $295 for the first month, including the current $25 first-month adjustment. The exact product, dose band, ongoing price, and eligibility are confirmed before enrollment.
The in-person compounded tirzepatide program starts at $475 per month, including medication; price varies by dose band. Depending on the selected medical weight-loss pathway, clinic support can include InBody scans, UltraSlim red-light support, Ballancer lymphatic care, Power Plate, nutrition guidance, and optional Quest laboratory work when clinically appropriate.
The virtual medical-management fee is $150 per month. Any prescribed Zepbound or Mounjaro product is paid separately to the dispensing pharmacy.
The Ankeny support fee is $300 per month. Applicable clinic support depends on the selected program, and any prescribed brand-name medication is paid separately to the dispensing pharmacy.
Before you request care
An ingredient, not a brand
An ingredient, not a brand · Zepbound and Mounjaro differ · Compounded is a separate category
Evidence and authority
The official Zepbound and Mounjaro prescribing information establishes the approved uses and safety information for each product.
Official resources
Still comparing?
WellForm can clarify the page, visit type, and information to bring without promising treatment before evaluation.
FAQ
Clear answers to the questions most likely to affect your decision.
A responsible next step
A physician-led visit separates the ingredient question from the product, indication, payment, and monitoring decisions.
